5T4

EQS-News: Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline

Retrieved on: 
수요일, 4월 10, 2024
Translocase, Partner, 5T4, Growth, Science, Patient, Doctor of Philosophy, Spacecraft, Andera-ye Olya, AACR, ADC, Annual general meeting, Fine chemical

Tubulis is developing a pipeline of uniquely matched antibody drug conjugates (ADCs) with an indication-tailored targeting molecule and payload combination to develop novel ADCs with superior properties.

Key Points: 
  • Tubulis is developing a pipeline of uniquely matched antibody drug conjugates (ADCs) with an indication-tailored targeting molecule and payload combination to develop novel ADCs with superior properties.
  • The proceeds of the Series B2 will primarily support progress in Tubulis’ pipeline of next-generation ADCs toward clinical evaluation and help achieve clinical proof-of-concept for lead candidates, TUB-040 and TUB-030.
  • The company expects to start its first Phase 1/2a clinical trial, including dose escalation and dose optimization cohorts in 2024.
  • “This substantial financing from a syndicate of global specialist biotech investors recognizes Tubulis’ unique position in the ADC space.

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Retrieved on: 
월요일, 4월 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Ovarian cancer, Translocase, 5T4, Cell, NSCLC, Adenocarcinoma, Patient, Neoplasm, Immunoglobulin G, Cancer, Cancer research, Spacecraft, Translation, Abstract, AACR, ADC, Non-small-cell lung cancer, Vaccine

Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

Key Points: 
  • Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
  • The poster presentations contained preclinical data, highlighting the ability of the two next-generation Tubutecan ADCs to create effective and durable responses even in low target-expressing tumor mouse models.
  • Tubulis is leveraging a proprietary suite of platform technologies to build a pipeline of uniquely matched ADC candidates that combine the right targeting molecule, conjugation chemistry and payload to deliver the true therapeutic value of the ADC approach.
  • The company’s lead candidates, both targeting solid tumor indications, are in late-stage preclinical testing, with TUB-040 ready for clinical evaluation.

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Retrieved on: 
월요일, 4월 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toxicity, 5T4, Translational research, Autoimmunity, Risk, Trichloroethylene, SVP, Cancer, Protein, CD3, Translation, AACR, Doctor of Philosophy, MHC, ABCL, TCE, Safety, CD28, San Diego Convention Center, PSMA, Peptide, Pharmaceutical industry

Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space.

Key Points: 
  • Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space.
  • “Our data illustrate that we can repeatedly generate TCEs that maximize tumor-cell killing without inducing excessive cytokine release.
  • The data show that AbCellera’s IgG and heavy chain-only CD28-binding antibodies do not display superagonist activity — a property associated with toxicity.
  • “We look forward to advancing these programs with the aim of delivering powerful new medicines for patients.”

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Retrieved on: 
목요일, 3월 14, 2024
Lung cancer, TME, 5T4, Assistant, Patient, Lung, Tumor microenvironment, PM, PBMC, CD3, Neoplasm, NK, Escape Room, Drug resistance, PDE, Vaccine

REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported preclinical proof of concept data for its conditionally-activated tri-specific antibody platform.

Key Points: 
  • REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported preclinical proof of concept data for its conditionally-activated tri-specific antibody platform.
  • “Our tribody platform is differentiated with its dual engagers including its NK cell engager having a dual mechanism of action, in addition to the conditionally activated T cell engager.
  • We are excited about the potential of this platform to produce a pipeline of promising drug candidates that can be effective across numerous solid cancer tumors,” stated Gil Efron, Chief Executive Officer of Purple Biotech.
  • Purple Biotech’s cleavable capping technology confines the compound’s therapeutic activity to the local tumor micro environment (TME), which increases the anticipated therapeutic window in patients.

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Retrieved on: 
목요일, 3월 14, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Translocase, 5T4, Supervisory board, Patient, Doctor of Philosophy, Spacecraft, Quality of life, AACR, EQT, Therapy, ADC, Annual general meeting, Fine chemical

Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.

Key Points: 
  • Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.
  • The proceeds of the Series B2 will primarily support progress in Tubulis’ pipeline of next-generation ADCs toward clinical evaluation and help achieve clinical proof-of-concept for lead candidates, TUB-040 and TUB-030.
  • TUB-040 addresses tumor-antigen Napi2b, a well-characterized target in ovarian and lung cancer and TUB-030 targets 5T4, an antigen often overexpressed in solid tumors.
  • “This substantial financing from a syndicate of global specialist biotech investors recognizes Tubulis’ unique position in the ADC space.

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
화요일, 3월 5, 2024
Neoplasm, Cetuximab, Jefferies Group, Research, Chemistry, Nivolumab, Table, NETS, IRS, NK, Pancreatic cancer, Head, 5T4, DCR, Investigational New Drug, Escape Room, SCCHN, Interim, MD Anderson Cancer Center, Congress, Net, Three Months, International Financial Reporting Standards, CMC, Immune system, International, ESMO, Neutrophil extracellular traps, University, STAT3, AACR, CM24, Conference, Tumor microenvironment, MOA, IND, Insurance, Acquisition, ADS, Drug resistance, Food, Average cost, CEACAM1, PDAC, Administration, Patient, Pharmaceutical industry

REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • At the American Association for Cancer Research (AACR) Special Conference on pancreatic cancer, Purple Biotech presented new potential PDAC biomarker data for CM24.
  • In February 2023, Purple Biotech acquired a platform of conditionally activated T cell and NK cell engagers that selectively activate immune response within the tumor microenvironment.
  • As of December 31, 2023, Purple Biotech had cash and cash equivalents and short-term deposits of $15.3 million, compared to $31.7 million on December 31, 2022.

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024

Retrieved on: 
화요일, 3월 5, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Head, Neoplasm, Neck, DAR, Toxicity, Therapeutic index, Cancer, Spacecraft, AACR, Lung, ADC, Annual general meeting, Breast, Safety, Stomach, Human, Ovarian cancer, Immunoglobulin G, Adenocarcinoma, Abstract, Patient, Poster, DNA repair, Translocase, Cell death, Biology, Cancer research, Esophagus, DNA, 5T4, Pharmaceutical industry

Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.

Key Points: 
  • Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.
  • The results we will present at the AACR Annual Meeting will highlight the preclinical differentiation of our two lead candidates, TUB-030 and TUB-040.
  • The full abstracts will be published on March 22, 2024, in an online-only proceedings supplement to the AACR journal, Cancer Research.
  • The company will issue a press release detailing the full preclinical data following the presentation at AACR.

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Retrieved on: 
월요일, 6월 12, 2023
Antigen, Prostate-specific antigen, University, Oxford, Prostate cancer, Cancer, Prostate, Autoimmunity, Patient, STEAP1, Immune system, PAP, 5T4, Recurrence, PSA, Safety, Disease, Vaccine, Vaccitech

PCA001 is a multi-centre, Phase 1/2 clinical trial designed to determine the recommended Phase 2 regimen and evaluate the safety, efficacy, as measured by prostate-specific antigen (PSA) response, and T cell response of VTP-850 monotherapy in men with rising PSA after definitive local therapy for their disease (i.e., biochemical recurrence).

Key Points: 
  • PCA001 is a multi-centre, Phase 1/2 clinical trial designed to determine the recommended Phase 2 regimen and evaluate the safety, efficacy, as measured by prostate-specific antigen (PSA) response, and T cell response of VTP-850 monotherapy in men with rising PSA after definitive local therapy for their disease (i.e., biochemical recurrence).
  • VTP-850 is a next-generation prostate cancer immunotherapeutic candidate which utilizes Vaccitech’s sequential dosing approach of two proprietary nonreplicating viral vectors, ChAdOx and MVA.
  • The first phase of the trial is enrolling participants in the US, with plans to open further sites in Italy and Spain.
  • “When the immune system targets multiple molecules on tumor cells, it is generally harder for tumor cells to escape destruction by the immune system.”

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
화요일, 5월 16, 2023
PDAC, NETS, Table, Neoplasm, Survival, ICB, Protein, Acquisition, CEACAM1, Patient, 5T4, SAB, Coronavirus Scientific Advisory Board, NK, Research, NET, Net, CD8, Average cost, TME, Neutrophil extracellular traps, PD-1, Safety, Cancer, STAT3, AACR, International, Papillary thyroid cancer, Therapeutic index, American Association for Cancer Research, Biomarker, SOC, MD Anderson Cancer Center, Jefferies Group, Administration, CM24, University, TASE, Immune system, Escape Room, Infrared spectroscopy correlation table, CRC, IRS1, ADS, Cetuximab, Trial of the century, Drug resistance, State Administrative Expenses, Clinical trial, Tumor microenvironment, Nivolumab, Pharmaceutical industry, Vaccine

REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2023.

Key Points: 
  • The acquisition provides Purple Biotech with a technology platform for tri-specific antibody compounds and offers the potential to further expand to additional targets.
  • On March 16, 2023, Purple Biotech shared new results from exploratory analyses from a Phase 1 dose escalation study that assessed the safety and tolerability of CM24 plus nivolumab ( NCT04731467 ).
  • On April 19, 2023, Purple Biotech announced research findings at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando.
  • Purple Biotech announced on April 25, 2023, the inauguration of its Scientific Advisory Board (SAB).

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

Retrieved on: 
수요일, 2월 8, 2023
TASE, SOC, AACR, American Association for Cancer Research, Neutrophil extracellular traps, Purple, Tumor microenvironment, PD-1, IND, Humanitarian use licenses, Technology transfer, Jefferies Group, 5T4, Acquisition, ADSS, CMC, State Administrative Expenses, Metastasis, ADS, Therapeutic index, Survival, Conference, Drug resistance, Immune system, Drug development, NK, Patient, Neoplasm, Nivolumab, Cetuximab, Escape Room, NET, Administration, CM24, Research, PDAC, Pharmaceutical industry, Management, Lithium

REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the year and the three months ended December 31, 2022.

Key Points: 
  • “We are reporting our 2022 financial results which are in line with our plans,” said Gil Efron, Chief Executive Officer of Purple Biotech.
  • The acquisition provides Purple Biotech with a technology platform for tri-specific antibody compounds and offers the potential to further expand to additional targets.
  • Also after the close of fiscal 2022, Purple Biotech announced on January 3, 2023, a research collaboration with Mor Research Applications, the technology transfer subsidiary of Clalit Healthcare Services.
  • As of December 31, 2022, Purple Biotech had cash and cash equivalents, short- and long-term deposits of $31.7 million, compared to $47.4 million on December 31, 2021.